Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Amdipharm UK Limited, Capital House, 85 King William Street, London EC4N 7BL, UK
ATC Code: A03FA01 (Drugs For Functional Gastrointestinal Disorders – Propulsives)
The action of metoclopramide is closely associated with parasympathetic nervous control of the upper gastro-intestinal tract where it has the effect of encouraging normal peristaltic action. This provides for a fundamental approach to the control of those conditions where disturbed gastrointestinal motility is a common underlying factor.
Metoclopramide is metabolised in the liver and the predominant route of elimination of metoclopramide and its metabolites is via the kidney.
The clearance of metoclopramide is reduced by up to 70% in patients with severe renal impairment, while the plasma elimination half-life is increased (approximately 10 hours for a creatinine clearance of 10-50 mL/minute and 15 hours for a creatinine clearance <10 mL/minute).
In patients with cirrhosis of the liver, accumulation of metoclopramide has been observed, associated with a 50% reduction in plasma clearance.
No additional data available.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
